Several TAAs and their CTL epitopes expressed in HCC have been discovered over the past 10–15 years [6–9, 21–24] and several trials of TAA-derived peptides for the treatment of HCC (e.g., AFP, human telomerase reverse transcriptase, and glypican-3) have been performed [25–27]. Here, GPC3 is linked to hepatocellular carcinoma.